{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:37:48Z","timestamp":1784835468492,"version":"3.55.0"},"reference-count":93,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:sec id=\"ab-yrv220004-1\"><jats:title>Importance<\/jats:title><jats:p>Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous \u03bc-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In November 2019, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration sponsored a meeting to discuss the current evidence regarding potential treatments for OUD, including cannabinoids, psychedelics, sedative-hypnotics, and immunotherapeutics, such as vaccines.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yrv220004-2\"><jats:title>Observations<\/jats:title><jats:p>Consensus recommendations are presented regarding the most critical elements of trial design for the evaluation of novel OUD treatments, such as: (1) stage of treatment that will be targeted (eg, seeking treatment, early abstinence\/detoxification, long-term recovery); (2) role of treatment (adjunctive with or independent of existing OUD treatments); (3) primary outcomes informed by patient preferences that assess opioid use (including changes in patterns of use), treatment retention, and\/or global functioning and quality of life; and (4) adverse events, including the potential for opioid-related relapse or overdose, especially if the patient is not simultaneously taking maintenance MOR agonist or antagonist medications.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yrv220004-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Applying the recommendations provided here as well as considering input from people with lived experience in the design phase will accelerate the development, translation, and uptake of effective and safe therapeutics for individuals struggling with OUD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2022.4020","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T16:32:44Z","timestamp":1669825964000},"page":"84","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder"],"prefix":"10.1001","volume":"80","author":[{"given":"Brian D.","family":"Kiluk","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethea A.","family":"Kleykamp","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine and Dentistry, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, New York State Psychiatric Institute, New York"},{"name":"Department of Psychiatry, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Huhn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle M.","family":"Kampman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Harborview Medical Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzie L.","family":"Preston","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Therapeutics Research Branch, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Vandrey","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia L.","family":"Bergeria","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Bogenschutz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, NYU Grossman School of Medicine, New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall T.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Wisconsin\u2013Madison School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[{"name":"University of Rochester School of Medicine and Dentistry, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Finan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[{"name":"Department of Health Behavior, School of Public Health, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth J.","family":"Houtsmuller","sequence":"additional","affiliation":[{"name":"Patient-Centered Outcomes Research Institute, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas"},{"name":"Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances R.","family":"Levin","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, New York State Psychiatric Institute, New York"},{"name":"Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"McRae-Clark","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Raison","sequence":"additional","affiliation":[{"name":"Department of Human Development and Family Studies, School of Human Ecology, University of Wisconsin\u2013Madison"},{"name":"Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin\u2013Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Delix Therapeutics, Bedford, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Turk","sequence":"additional","affiliation":[{"name":"University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"434","key":"yrv220004r1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2595","article-title":"Medication development in opioid addiction: meaningful clinical end points.","volume":"10","author":"Volkow","year":"2018","journal-title":"Sci Transl Med"},{"issue":"8","key":"yrv220004r2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/add.12551","article-title":"The global epidemiology and burden of opioid dependence: results from the Global Burden of Disease 2010 study.","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"issue":"4","key":"yrv220004r3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000312","article-title":"High mortality among patients with opioid use disorder in a large healthcare system.","volume":"11","author":"Hser","year":"2017","journal-title":"J Addict Med"},{"issue":"1","key":"yrv220004r4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1172\/JCI134708","article-title":"Medications for opioid use disorders: clinical and pharmacological considerations.","volume":"130","author":"Volkow","year":"2020","journal-title":"J Clin Invest"},{"key":"yrv220004r6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.","volume":"85","author":"Morgan","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"10118","key":"yrv220004r7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"yrv220004r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review.","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"issue":"22","key":"yrv220004r9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"yrv220004r10","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.biopsych.2017.01.014","article-title":"Opioid use disorder: a desperate need for novel treatments.","volume":"81","author":"Fuehrlein","year":"2017","journal-title":"Biol Psychiatry"},{"issue":"4","key":"yrv220004r11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","article-title":"NIDA\u2019s medication development priorities in response to the opioid crisis: ten most wanted.","volume":"44","author":"Rasmussen","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"10182","key":"yrv220004r12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions.","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"yrv220004r13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamapsychiatry.2021.0259","article-title":"Moving beyond medications that act at the \u00b5 receptor in the treatment of opioid use disorder.","volume":"78","author":"Strain","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"yrv220004r16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13063-019-3995-y","article-title":"A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder.","volume":"21","author":"Dennis","year":"2020","journal-title":"Trials"},{"key":"yrv220004r17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fmed.2019.00082","article-title":"Patient preference studies during early drug development: aligning stakeholders to ensure development plans meet patient needs.","volume":"6","author":"Cook","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"yrv220004r18","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.2105\/AJPH.2009.184036","article-title":"Community-based participatory research contributions to intervention research: the intersection of science and practice to improve health equity.","volume":"100","author":"Wallerstein","year":"2010","journal-title":"Am J Public Health"},{"issue":"2","key":"yrv220004r19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1370\/afm.2042","article-title":"The PCORI Engagement Rubric: promising practices for partnering in research.","volume":"15","author":"Sheridan","year":"2017","journal-title":"Ann Fam Med"},{"issue":"7","key":"yrv220004r20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2019.0077","article-title":"Should physicians recommend replacing opioids with cannabis?","volume":"321","author":"Humphreys","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"yrv220004r21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tins.2016.12.006","article-title":"Cannabidiol: swinging the marijuana pendulum from \u2018weed\u2019 to medication to treat the opioid epidemic.","volume":"40","author":"Hurd","year":"2017","journal-title":"Trends Neurosci"},{"issue":"4","key":"yrv220004r22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s13311-015-0373-7","article-title":"Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage.","volume":"12","author":"Hurd","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"1","key":"yrv220004r23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12954-017-0183-9","article-title":"Rationale for cannabis-based interventions in the opioid overdose crisis.","volume":"14","author":"Lucas","year":"2017","journal-title":"Harm Reduct J"},{"key":"yrv220004r24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"yrv220004r25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.drugalcdep.2015.09.031","article-title":"Safety of oral dronabinol during opioid withdrawal in humans.","volume":"157","author":"Jicha","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"yrv220004r26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.drugalcdep.2016.05.002","article-title":"Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.","volume":"164","author":"Lofwall","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yrv220004r27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/can.2018.0022","article-title":"Emerging evidence for cannabis\u2019 role in opioid use disorder.","volume":"3","author":"Wiese","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"yrv220004r28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm.","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"yrv220004r29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: a review.","volume":"24","author":"Garcia-Romeu","year":"2016","journal-title":"Exp Clin Psychopharmacol"},{"issue":"7","key":"yrv220004r30","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"yrv220004r31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey.","volume":"10","author":"Garcia-Romeu","year":"2020","journal-title":"Front Psychiatry"},{"issue":"5","key":"yrv220004r32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States.","volume":"31","author":"Pisano","year":"2017","journal-title":"J Psychopharmacol"},{"key":"yrv220004r33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do.","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"yrv220004r34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugpo.2018.11.006","article-title":"The tripping point: the potential role of psychedelic-assisted therapy in the response to the opioid crisis.","volume":"66","author":"Argento","year":"2019","journal-title":"Int J Drug Policy"},{"key":"yrv220004r35","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1111\/pme.12910","article-title":"Opioid therapy and sleep disorders: risks and mitigation strategies.","volume":"16","author":"Cheatle","year":"2015","journal-title":"Pain Med"},{"key":"yrv220004r36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.brainresbull.2016.01.012","article-title":"Ecological momentary assessment of affect and craving in patients in treatment for prescription opioid dependence.","volume":"123","author":"Huhn","year":"2016","journal-title":"Brain Res Bull"},{"key":"yrv220004r37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.addbeh.2016.08.026","article-title":"Daily sleep quality affects drug craving, partially through indirect associations with positive affect, in patients in treatment for nonmedical use of prescription drugs.","volume":"65","author":"Lydon-Staley","year":"2017","journal-title":"Addict Behav"},{"issue":"2","key":"yrv220004r38","first-page":"140","article-title":"Crosstalk between sleep disturbance and opioid use disorder: a narrative review.","volume":"12","author":"Fathi","year":"2020","journal-title":"Addict Health"},{"key":"yrv220004r39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.addbeh.2017.11.001","article-title":"Using ecological momentary assessment to assess the temporal relationship between sleep quality and cravings in individuals recovering from substance use disorders.","volume":"83","author":"Freeman","year":"2018","journal-title":"Addict Behav"},{"issue":"6","key":"yrv220004r40","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/add.v112.6","article-title":"Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994.","volume":"112","author":"Dolsen","year":"2017","journal-title":"Addiction"},{"issue":"5","key":"yrv220004r41","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41386-020-0619-x","article-title":"Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?","volume":"45","author":"James","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"yrv220004r42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose.","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"yrv220004r43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41386-018-0197-3","article-title":"Vaccines to treat opioid use disorders and to reduce opioid overdoses.","volume":"44","author":"Baehr","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"yrv220004r44","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs.","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"yrv220004r45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","article-title":"Animal models and the development of vaccines to treat substance use disorders.","volume":"126","author":"Ohia-Nwoko","year":"2016","journal-title":"Int Rev Neurobiol"},{"key":"yrv220004r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107730","article-title":"Vaccine blunts fentanyl potency in male rhesus monkeys.","volume":"158","author":"Tenney","year":"2019","journal-title":"Neuropharmacology"},{"issue":"10","key":"yrv220004r47","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41386-019-0385-9","article-title":"Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats.","volume":"44","author":"Townsend","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"yrv220004r48","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacotherapies for treating opioid use disorder.","volume":"39","author":"Banks","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"yrv220004r49","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108653","article-title":"Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder.","volume":"195","author":"Raleigh","year":"2021","journal-title":"Neuropharmacology"},{"issue":"3","key":"yrv220004r50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.120.000124","article-title":"Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats.","volume":"375","author":"Baehr","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"yrv220004r51","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. a controlled study.","volume":"28","author":"Savage","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"1-3","key":"yrv220004r52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.drugalcdep.2011.06.026","article-title":"Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial.","volume":"120","author":"Stein","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"yrv220004r53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3923\/jpt.2009.30.35","article-title":"Immunotherapy of 347 volunteer outpatient morphine addicts by human therapeutic morphine vaccine in Kermanshah Province of Iran.","volume":"4","author":"Akbarzadeh","year":"2009","journal-title":"J Pharmacol Toxicol"},{"key":"yrv220004r55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neubiorev.2019.06.007","article-title":"Transcranial electrical and magnetic stimulation (tES and TMS) for addiction medicine: a consensus paper on the present state of the science and the road ahead.","volume":"104","author":"Ekhtiari","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"yrv220004r56","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials.","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"yrv220004r57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them.","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"issue":"2","key":"yrv220004r58","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction.","volume":"10","author":"Dugosh","year":"2016","journal-title":"J Addict Med"},{"issue":"14","key":"yrv220004r59","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the design and interpretation of noninferiority trials.","volume":"377","author":"Mauri","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"yrv220004r60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2020.3940","article-title":"Treating patients with opioid use disorder in their homes: an emerging treatment model.","volume":"324","author":"Uscher-Pines","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"yrv220004r62","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1093\/ntr\/ntaa105","article-title":"Remote methods for conducting tobacco-focused clinical trials.","volume":"22","author":"Dahne","year":"2020","journal-title":"Nicotine Tob Res"},{"issue":"1","key":"yrv220004r63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12954-020-00394-z","article-title":"A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.","volume":"17","author":"Crowley","year":"2020","journal-title":"Harm Reduct J"},{"issue":"3","key":"yrv220004r64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/00952990.2019.1658197","article-title":"A novel telehealth platform for alcohol use disorder treatment: preliminary evidence of reductions in drinking.","volume":"46","author":"Mitchell","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"yrv220004r65","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary care\u2013based models for the treatment of opioid use disorder: a scoping review.","volume":"166","author":"Korthuis","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"yrv220004r66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-020-01149-0","article-title":"Identification and management of opioid use disorder in primary care: an update.","volume":"22","author":"Donroe","year":"2020","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"yrv220004r67","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/02698811211055855","article-title":"Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: qualitative results from a proof-of-concept study.","volume":"36","author":"Hendricks","year":"2022","journal-title":"J Psychopharmacol"},{"issue":"3","key":"yrv220004r68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/02698811211069103","article-title":"Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 \u00b5g LSD in healthy participants within a novel intervention paradigm: a proof-of-concept study.","volume":"36","author":"Family","year":"2022","journal-title":"J Psychopharmacol"},{"key":"yrv220004r69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jsat.2015.09.006","article-title":"Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: an integrative literature review.","volume":"61","author":"Priester","year":"2016","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"yrv220004r70","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018.","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"yrv220004r71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","article-title":"Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.","volume":"41","author":"Gordon","year":"2020","journal-title":"Subst Abus"},{"key":"yrv220004r72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jsat.2018.04.003","article-title":"Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States.","volume":"89","author":"Short","year":"2018","journal-title":"J Subst Abuse Treat"},{"key":"yrv220004r73","doi-asserted-by":"publisher","DOI":"10.1016\/j.abrep.2020.100287","article-title":"Hispanic participants in the National Institute on Drug Abuse\u2019s Clinical Trials Network: a scoping review of two decades of research.","volume":"12","author":"Eghaneyan","year":"2020","journal-title":"Addict Behav Rep"},{"key":"yrv220004r74","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drugalcdep.2019.05.017","article-title":"A current re-examination of racial\/ethnic disparities in the use of substance abuse treatment: do disparities persist?","volume":"202","author":"Pinedo","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yrv220004r75","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/1475-6773.12686","article-title":"Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees.","volume":"53","author":"Abraham","year":"2018","journal-title":"Health Serv Res"},{"key":"yrv220004r76","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.drugalcdep.2018.06.006","article-title":"Treatment outcome disparities for opioid users: are there racial and ethnic differences in treatment completion across large US metropolitan areas?","volume":"190","author":"Stahler","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"yrv220004r77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/ajad.13051","article-title":"A literature review examining primary outcomes of medication treatment studies for opioid use disorder: what outcome should be used to measure opioid treatment success?","volume":"29","author":"Biondi","year":"2020","journal-title":"Am J Addict"},{"issue":"1","key":"yrv220004r79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/add.v114.1","article-title":"What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?","volume":"114","author":"Kiluk","year":"2019","journal-title":"Addiction"},{"key":"yrv220004r80","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107857","article-title":"Within-treatment frequency of use versus abstinence as a predictor of longitudinal post-treatment follow-up assessments of drug use.","volume":"208","author":"Fitzmaurice","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yrv220004r81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"8","key":"yrv220004r82","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/add.v114.8","article-title":"Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?","volume":"114","author":"Marsden","year":"2019","journal-title":"Addiction"},{"key":"yrv220004r83","doi-asserted-by":"publisher","DOI":"10.1111\/acer.2018.42.issue-8","article-title":"Change in DSM-5 alcohol use disorder criteria count and severity level as a treatment outcome indicator: results from a randomized trial.","author":"Kiluk","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"yrv220004r84","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jsat.2011.05.001","article-title":"Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study.","volume":"41","author":"Cousins","year":"2011","journal-title":"J Subst Abuse Treat"},{"key":"yrv220004r85","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"5","key":"yrv220004r86","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ADM.0000000000000235","article-title":"Brief Opioid Overdose Knowledge (BOOK): a questionnaire to assess overdose knowledge in individuals who use illicit or prescribed opioids.","volume":"10","author":"Dunn","year":"2016","journal-title":"J Addict Med"},{"issue":"3","key":"yrv220004r87","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1592\/phco.31.3.262","article-title":"Drug misuse and diversion in adults prescribed anxiolytics and sedatives.","volume":"31","author":"McLarnon","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"6","key":"yrv220004r88","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamapsychiatry.2017.0724","article-title":"US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013.","volume":"74","author":"Hasin","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"yrv220004r89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/cpt.v103.4","article-title":"Psychedelic drugs as therapeutics: no illusions about the challenges.","volume":"103","author":"Sellers","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"yrv220004r90","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"yrv220004r91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108530","article-title":"Potential unintended consequences of class-wide drug scheduling based on chemical structure: a cautionary tale for fentanyl-related compounds.","volume":"221","author":"Comer","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"yrv220004r92","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109398","article-title":"Trends in seizures of powders and pills containing illicit fentanyl in the United States, 2018 through 2021.","volume":"234","author":"Palamar","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"yrv220004r93","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/jat\/bkaa115","article-title":"A 2017-2019 update on acute intoxications and fatalities from illicit fentanyl and analogs.","volume":"45","author":"Brunetti","year":"2021","journal-title":"J Anal Toxicol"},{"key":"yrv220004r5","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"yrv220004r61","volume-title":"Telehealth-Delivered Opioid Agonist Therapy for the Treatment of Adults With Opioid Use Disorder: Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines","author":"Ho","year":"2018"},{"key":"yrv220004r14","unstructured":"Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks. Consortium for Addiction Research on Efficacy and Safety (CARES). Accessed June 10, 2022. https:\/\/www.acttion.org\/cares"},{"key":"yrv220004r15","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. Accessed July 27, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input"},{"key":"yrv220004r54","unstructured":"Clinical Trials of Multivalent Opioid Vaccine Components. ClinicalTrials.gov identifier: NCT04458545. Updated July 5, 2022. Accessed August 20, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04458545"},{"key":"yrv220004r78","unstructured":"US Food and Drug Administration. Opioid use disorder: endpoints for demonstrating effectiveness of drugs for treatment guidance for industry. Accessed July 27, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/opioid-use-disorder-endpoints-demonstrating-effectiveness-drugs-treatment-guidance-industry"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2799201\/jamapsychiatry_kiluk_2022_rv_220004_1671567505.76247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:02:22Z","timestamp":1672848142000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2799201"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.4020","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}